Corbus Pharmaceuticals (NASDAQ: NASDAQ:CRBP) has received a boost from Oppenheimer, as the firm increased the stock's price target to $88 from the previous $80. The rating remains at Outperform.
The adjustment, on Wednesday, follows Corbus's second-quarter results, which were closely watched by investors for insights into the potential of CRBP's drug candidate CRB-913. This interest was particularly piqued by comparisons to a Phase 2 study by another company.
Corbus provided updates on the clinical development timelines for CRB-913 and another candidate, CRB-601. Additionally, the company outlined milestones for a third drug, CRB-701, including expected interim data due early in 2025.
The financial position of Corbus was strengthened by approximately $36 million in proceeds from at-the-market (ATM) offerings during the second quarter and an additional $29 million early in the third quarter, which has been factored into updated financial models.
The decision to raise the price target is rooted in the firm's confidence in the CRB-913 drug candidate. The analyst's comments reflect a positive outlook for the drug's progression, which contributed to the revised price target. Corbus's solid cash position, bolstered by recent capital raises, provides a stable foundation for continued development and trials.
Corbus's stock may see increased interest as investors and analysts alike monitor the company's progress in advancing its clinical programs. The anticipation of interim data for CRB-701 adds another layer of potential developments to watch in the coming year.
Corbus has seen significant developments, particularly in its drug candidates CRB-913 and CRB-701. B.Riley initiated coverage on Corbus with a Buy rating, highlighting the potential of both drugs. CRB-913, a weight loss agent, and CRB-701, a promising drug in cervical cancer treatment, are the focal points of the firm's optimism.
Meanwhile, RBC Capital Markets and Oppenheimer have maintained an Outperform rating on Corbus, reflecting their confidence in the company's growth prospects. Both firms have raised their price targets for Corbus' shares, with RBC Capital setting a target of $82 and Oppenheimer raising their target to $80.
InvestingPro Insights
As Corbus Pharmaceuticals (NASDAQ:CRBP) garners attention with its updated price target from Oppenheimer, real-time data from InvestingPro provides additional context to the company's financial health and market performance. Corbus has demonstrated a strong cash position, holding more cash than debt on its balance sheet, which aligns with the firm's confidence in CRBP's drug candidate CRB-913. However, analysts have revised their earnings downwards for the upcoming period, which may be a point of consideration for investors.
InvestingPro data reveals a market capitalization of $565.75 million, highlighting the company's size in the pharmaceutical space. Despite not being profitable over the last twelve months, Corbus has shown significant stock price appreciation with a year-to-date price total return of 776.49% and a six-month price total return of 120.4%. The company's stock price volatility is evident, with a 10.98% drop over the last week, but a substantial 33.12% return over the last three months. These metrics suggest a highly dynamic market sentiment surrounding Corbus.
Investors considering Corbus should note that the company does not pay a dividend, prioritizing reinvestment into its clinical programs. For those seeking more detailed analysis and additional InvestingPro Tips, such as insights on gross profit margins or the significance of the company's Price/Book multiple, there are 12 more tips available at InvestingPro, which can further guide investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.